Awareness, Knowledge and Attitudes about human papillomavirus infection and vaccination among university students in Astana by Shokanbayeva, Torgyn
 Awareness, Knowledge and Attitudes about human papillomavirus infection 
and vaccination among university students in Astana 
  
(A cross-sectional study) 
 
 
 
 
Master of Public Health Thesis Project Utilizing Professional Publication Framework 
 
 
Torgyn Shokanbayeva 
MPH Candidate 
 
 
 
 
 
 
 
 
Primary advisor: Raushan Alibekova, MD, MPH, PhD 
Secondary advisor: Azliyati Azizan, MS, PhD 
 
 
 
Master of Public Health Program 
Nazarbayev University School of Medicine 
Astana, Kazakhstan, 2018 
2 
 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS.............................................................................................................3 
ABSTRACT ...................................................................................................................................4 
1. INTRODUCTION.....................................................................................................................5 
1.1 BACKGROUND/ LITERATURE REVIEW............................................................................5 
1.2 LACK OF PUBLIC HEALTH RESEARCH IN FIELD OF HPVSTUDY.............................7 
1.3 OBJECTIVES OF THE STUDY……………………...............................................................8 
2. RESEARCH METHODOLOGY.............................................................................................8 
2.1 STUDY DESIGN…...................................................................................................................8 
2.2 STUDY POPULATION ...........................................................................................................9 
2.3 SAMPLING METHODOLOGY ............................................................................................10 
2.4 SAMPLE SIZE .......................................................................................................................11 
2.5 STUDY INSTRUMENT.........................................................................................................12 
2.6 PILOT STUDY........................................................................................................................14 
2.7 DATA COLLECTION............................................................................................................14 
3. ETHICAL CONSIDERATIONS ...........................................................................................14 
4. DATA ANALYSIS...................................................................................................................15 
4.1 DATA ENTRY AND CLEANING.........................................................................................15 
4.1 STATISTICAL ANALYSIS...................................................................................................15 
5. RESULTS.................................................................................................................................17 
6. DISCUSSION...........................................................................................................................21 
7. STUDY LIMITATIONS.........................................................................................................24 
8. CONCLUSION AND RECOMMENDATION.....................................................................25 
REFERENCE LIST ....................................................................................................................27 
APPENDIX 1. TABLES..............................................................................................................31 
APPENDIX 2. QUESTIONNAIRE (ENGLISH, KAZAKH, RUSSIAN)..............................47 
APPENDIX 3. CONSENT FORM (ENGLISH, KAZAKH, RUSSIAN) ..............................63 
 
 
 
3 
 
 
ACKNOWLEDGMENTS 
I would like to express deep acknowledgment to my advisors Dr. Raushan Alibekova and 
Dr. Azliyati Azizan for their great contribution to this project. Despite their busy schedules, my 
advisors committed their time to keep track of my progress and to give me feedback at each 
stage of this project. With their valuable advises I was able to overcome those difficulties faced 
during study planning and study implementation. 
I am grateful to all faculty members of the School of Medicine at Nazarbayev Unversity, 
especially to Dr. Byron Crape for his great support during the whole study period and his 
assistance in the consult of the study. 
I am also thankful to the students, to the faculty, and to the administration of Nazarbayev 
University, Eurasian National University, Astana Medical University, and Kazakh Agrotechnical 
University, especially to Assiya Turganbayeva, Zhanerke Tleukulova, Saule Tardzhibayeva, and 
Makpal Dzhaxymbetova for their willingness to cooperate and for giving me a permission to 
conduct this study. 
I also would like to express my gratitude to my MPH classmates, my family and friends 
for their encouragement and support during these two years of study. 
 
 
 
 
 
4 
 
ABSTRACT 
Background 
Human Papilloma virus is one of the most common infections caused by a virus. Most 
importantly is the fact that this infection can lead to cervical cancer, which represents a great 
burden for Kazakhstani women.  There is a vaccine to prevent cervical cancer. Kazakhstan has 
introduced human papilloma virus vaccination program. However, there are no published public 
health studies about behavioral perception towards HPV and HPV vaccination that could support 
and encourage such a vaccination program.  
Aims of the study 
The aim of this study was to explore university students’ awareness, knowledge, and attitudes 
towards HPV and HPV vaccination, by determining the level of HPV infection knowledge 
among university students, the attitudes and beliefs of university students towards the HPV 
infection and vaccine, and the willingness of the students for HPV vaccine uptake. Moreover, 
this study aimed to identify the differences in awareness and attitudes towards HPV infection and 
vaccination by socio-demographic and behavioral characteristics. 
Methodology 
The study design was cross-sectional which utilized the framework of knowledge, attitude, and 
practice. Sample size for this study was 392. Study population consisted of bachelor and 
graduate students studying at Nazabayev University, Kazakh Agricultural University, Eurasian 
National University, and Medical University of Astana and aged between 16 and 30 years. 
Simple random sampling was used to create the list of universities included in the study. Data 
were collected through paper based questionnaires which required 15 minutes to be completed. 
The independent variables were sociodemographic and behavioral characteristics of the 
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participants. In this study there were three dependent variables: knowledge about HPV and HPV 
vaccination, attitudes towards HPV vaccination, and intention to receive the vaccine. Univariate, 
bivariate, and multivariate logistic regression were performed in order to obtain the results of the 
study. 
Results 
Mean age of participants was 19 ± 2.3 years, and 69.6 % were women. 51.8% of respondents 
heard about HPV and 37% heard about HPV vaccination prior to the study. University lectures 
or professor were the main source of information for those students who answered that they 
heard about HPV vaccination. 41% of students had high level of knowledge, 49% of students 
had positive attitudes towards HPV vaccine and intention to receive the vaccine. Variables such 
as age, family income, whether the student heard about HPV and HPV vaccine, and alcohol 
consumption were found as significant predictors of the knowledge score. Only whether the 
student heard about HPV before the study was statistically associated with attitudes towards 
HPV vaccination. Intention score to receive HPV vaccination was statistically associated with 
academic performance of the student, whether the student heard about HPV and HPV 
vaccination prior to the study, or whether the student uses contraception.  
Conclusion 
Overall, this study revealed low level of knowledge among the majority of students. In contrast 
there were more students with high attitude score to the vaccine and high intention score to 
receive the vaccine. This study could contribute to the improvement of the existing vaccination 
policy in Kazakhstan and educational policy as well.  
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1. Introduction 
1.1 Background/Literature Review 
Human papillomavirus (HPV) is considered to be the most common viral infection that 
affects reproductive tract (World Health Organization, 2018). Among the general populations, 
prevalence of HPV varies from 7-14% (Raychaudhuri and Mandal, 2012). Moreover, HPV is 
responsible for almost all cases of cervical cancer and is the cause of a great proportion of other 
anogenital and head and neck cancer (Bruni et al., 2017). In addition, HPV may lead to recurrent 
juvenile respiratory papillomatosis and genital warts, mainly caused by HPV types 6 and 
11(Lacey, Lowndes and Shah, 2006). There are several type of HPV; of particularly concern are 
HPV types 16 and 18 which account for about 70% of all cases of cervical cancer worldwide 
(Clifford et al., 2006). One of the well-recognized modes of transmission of HPV is skin-to-skin 
genital contact (World Health Organization, 2018). Therefore, right after both men and women 
become sexually active it is the highest point of time to acquire the infection(Khan et al., 2016). 
  On a worldwide scale, cervical cancer is the fourth leading cause of death among females 
and is also the third most diagnosed type of cancer (Jemal, Bray and Ferlay, 1999). According to 
the data from International Agency for Research on Cancer, every year there are 530,000 new 
registered cases of cervical cancer with 275,000 mortalities (Ferlay et al., 2010). More than 85% 
of deaths take place in countries with low- and middle-income economies (Hopkins and Wood, 
2013). There are several risk factors known to increase the incidence of cervical cancer such as 
early marriage, multiple sexual partners, poor practice of personal hygiene, oral contraceptives, 
HIV co-infection, smoking, and low socioeconomic status (Raychaudhuri and Mandal, 2012). 
On the Kazakhstani scale, cervical cancer also represents a major threat to public health. 
Moreover, according to Bruni et al. (2017), in Kazakhstan every year 2789 women are diagnosed 
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with cervical cancer from which 982 women die. Apart from that cervical cancer is the second 
most frequent cancer among women and is the first most frequent cancer among women aged 
between 15 and 44 years with the age-specific incidence of 36 (Bruni et al., 2017). 
Epidemiological study in Kazakhstan revealed that between 1999 and 2008 the average age of 
cervical cancer patients was 53.5±0.7 years (Igissinov et al., 2012).  
Unlike cases with other cancers, there is a vaccination to prevent HPV infection and from 
patients developing cervical cancer. Nowadays, two brands of HPV vaccines are available on a 
commercial basis. There is evidence to support that both of these vaccines provide almost full 
protection for the following HPV strains (Schiffman and Wacholder, 2012). Cervarix and 
Gardasil are able to protect from 16 and 18 oncogenic strains, while the second one is also able 
to protect from 6 and 11 HPV strains (Hopkins and Wood, 2013). These vaccines are 
recommended before the first sexual activity and are offered as 3 doses over a period of 6 
months (Bosch et al., 2012). The price for both of the vaccines for the necessary three shots is 
equal to more than US$300 (Lancet, 2011). Therefore, due to such relatively high price, these 
vaccination offers might not be affordable for every country of the world.  
By 2010, 33 countries had introduced HPV vaccination programs into the health care 
systems, and there were few developing countries among them (Lancet, 2011). Kazakhstan was 
exception from those countries, and introduced HPV vaccination policy only few years later. In 
2013 the government has introduced the National HPV Immunization program that targeted 11-
12 year old females in Atyrau and Pavlodar regions, and Almaty and Astana cities (Bruni et al., 
2017). Moreover, Kazakhstani media have reported unsuccessful case of vaccination of a female 
in Pavlodar, which caused resonance to the acceptance of the vaccine (Tengrinews.kz, 2018). 
Although media claim that vaccination still exists there is no information on details of the 
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program and the reported HPV vaccination coverage. Therefore, it is difficult to discuss the 
success of the vaccination program in Kazakhstan.  
1.2 Lack of public health research in field of HPV  
Although some data are available, it is clear that there is lack of research on the topic of 
HPV in Kazakhstan. There were found published studies on the topics of  HPV epidemiology in 
Kazakhstan (Igissinov et al., 2012), prevalence and genotyping of HPV in Kazakhstan 
(Niyazmetova et al., 2017), and HPV and P16 expression in oral and oropharyngeal cancer in 
Kazakhstan (Adilbay et al., 2018). However, there was not found any published research to 
explore public knowledge and understanding of HPV as well attitudes towards HPV vaccination. 
It is important to note that learning about behavioral perception towards HPV vaccination is an 
essential requirement to develop a health policy that will support HPV vaccination among 
population (Dany, Chidiac and Nassar, 2015). 
Unlike in Kazakhstan, there are many studies done abroad that use knowledge, attitudes 
and practice assumption (KAP) framework to study HPV and HPV vaccination. These studies 
did not only focus on the level of knowledge and perception of HPV infection and vaccination, 
but they also demonstrated various associations with sociodemographic variables. A cross-
sectional study conducted among medical students of Malaysia showed that students from 
clinical year group had a better knowledge and higher proportion to accept HPV vaccine (Shafei 
et al., 2014). Moreover, similar study conducted in Lebanon demonstrated that students coming 
from graduate programs and health related majors, and those who are vaccinated had 
significantly higher knowledge scores of HPV infection (Dany, Chidiac and Nassar, 2015). Yet 
the results of the study by Khan et al. (2016) revealed that students have poor understanding 
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about the health problems associated with HPV, its prevention, modes of transmission and 
availability of HPV vaccine in Pakistan. 
Given the fact that HPV represents a burden for the public of Kazakhstan and there is 
lack of public health research, this study explored university students’ awareness, knowledge, 
and attitudes towards HPV and HPV vaccination. The results of this study will provide the 
baseline knowledge and understanding of students. Moreover the results of the study may also 
assist Kazakhstani government to adopt the changes to the existing policy to improve the 
vaccination program.  
1.3 Objectives of the study 
1) To determine the level of HPV infection knowledge among university students.  
2) To determine the attitudes and beliefs of university students towards the HPV infection and 
vaccine.  
3) To identify the willingness of the students for HPV vaccine uptake.  
4) To identify the differences in awareness and attitudes towards HPV infection and vaccination 
by socio-demographic and behavioral characteristics. 
2. Research Methodology 
2.1  Study Design 
A cross-sectional survey about HPV and HPV vaccination was conducted among Astana 
students between January and February 2018 to describe their knowledge about HPV and HPV 
vaccination, attitudes towards HPV vaccination, and intention score to receive the vaccine. This 
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quantitative study utilized the framework of knowledge, attitude, and practice. This study 
involved primary data collection by administering a structured paper based questionnaire. 
There were several reasons to select cross-sectional design for this study. First of all cross 
sectional study is the best option to identify the prevalence and to find the association between 
variables that can be further used in cohort or randomized clinical trial studies (Mann, 2003). 
Secondly, this type of study design is quick and cheap to implement (Mann, 2003). Therefore, 
fewer resources are required to run the study. However, one of the major limitations of cross-
sectional study is that it does not differentiate between cause and effect from simple association 
(Mann, 2003). But still the purpose of the study is not to establish cause and effect, but only the 
association between socio demographic variables and knowledge of HPV and HPV vaccine, 
attitudes towards HPV vaccination, and intention score to receive HPV vaccination. Therefore, 
taking into consideration both strengths and limitations cross sectional research design is the best 
option to study this research question given limited time and resources.  
2.2 Study Population 
Eligible participants for this study were students who were enrolled at multiprofilе 
universities (which offer different disciplines of study majors) or in the medical universities 
where the number of students is high. In terms of level of age and level of study, bachelor or 
undergraduate students were recruited for participation in the study.  
It is important to note that graduate level students were also included in this study as 
educational programs at the Nazarbayev University School of Medicine are only offered at the 
graduate level. Therefore, the eligible age range for this study was assumed to vary from 16 to 
around 30 years. 
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Particularly for this study, three multiprofile universities (Nazarbayev University, Kazakh 
Agricultural University, and Eurasian National University) and one medical university (Astana 
Medical University) were chosen. These are the largest universities of Astana city in terms of 
number of students and which offer a wide range of specialties for prospective students. Eurasian 
National University offers 65 undergraduate programs and 97 graduate programs while Kazakh 
Agricultural University offers 37 undergraduate and 42 graduate programs (Granty 2017-2018 
Kazakhstanskiye VUZy, instituty i universitety, 2018). Nazarbayev University, also offers a 
wide range of programs as it has 8 different schools. Astana Medical University offers only 6 
undergraduate and 8 graduate programs, but still the number of students is high. In total there are 
4269 students at Nazarbayev University, 4552 students at Astana Medical University, 8971 
students at Eurasian National University, and 10064 students at Kazakh Agricultural University. 
Taking into consideration the differences between universities and in order to ensure 
comparability between students, certain faculties were chosen for the study.  Students were 
chosen from the following faculties of the universities: Astana Medical University (Deanery of 
the faculty public health, pharmacy, stomatology, Deanery of general medicine); Nazarbayev 
University (School of Science and Technology, School of Humanities and Social Sciences, 
School of Medicine), Eurasian National University (Faculty of Natural Sciences, Faculty of 
Mechanics and Mathematics, Faculty of Journalism and Political Science, Faculty of Transport 
and Energy); Kazakh Agricultural University ( Faculty of Veterinary Sciences and Animal 
Husbandry, Energy Department, Humanitarian Faculty, Technical Faculty). 
            2.3 Sampling methodology 
This study involved two methods of sampling. First stage of sampling involved random 
selection of the biggest university of Astana, both in terms of students’ number and the variety of 
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study programs offered. The second stage of sample selection involved non-random convenience 
sampling. As universities were chosen, authorities of the universities were approached to obtain 
permission for the study. After that, the university authorities assigned certain groups to undergo 
the survey. Therefore, students were approached based on availability criteria.  
  It is important to note that according to Kazakhstani educational system students of the 
universities study in one particular group from the beginning until the end of their studies. In 
case of Nazarbayev University, student study in one particular group only at the graduate level.  
2.4 Sample size  
  Total sample size was identified by using STAT CALC option in EPI INFO free 
software. Total sample size was estimated to be 518 people based on a confidence interval of 
95%, significance level of 0.05, and power of 80%. In this software sample size was estimated 
by using the method of Fleiss with a continuity correction , which can be found below (Sullivan 
and Soe, 2007).  Where in this formula, n1 stands for number of exposed, n2 stands for number 
of unexposed, r for ratio of unexposed to exposed, p1 for proportion of exposed with outcome of 
interest, and p2 is the proportion of unexposed with outcome. 
𝑛 = 𝑛1 [1 + √1 +
2(𝑟 + 1)
𝑛1|𝑝2 − 𝑝1|
] 
Data for calculating sample size data was obtained from previous study on knowledge 
about cervical cancer early warning signs and symptoms, risk factors and vaccination among 
students at a medical school conducted in Al-Ahsa, Kingdom of Saudi Arabia.  According to 
findings of the study awareness about of the availability of HPV vaccine was different among 
male and female students, and was equal to 38.7% for males and 27. 2% for females (A.A. et al., 
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2014). Therefore, outcome variable is awareness about of the availability of HPV vaccine, and 
exposed group are female students.  
In Kazakhstan there is approximately equal distribution of males and females, which are 
8,726,100 and 9,388,400 respectively (Bruni et al., 2017). Therefore, it can be assumed that there 
is also equal distribution of gender at universities. Accordingly the same gender distribution was 
assumed for this study. 
However, taking into consideration 80% response rate and 90% eligibility rate, the total 
sample size was increased to 673.  
2.5 The Study Instrument (The questionnaire itself) 
.  This cross-sectional survey used validated questionnaire on HPV knowledge, attitudes 
and practices from the study by Dany, Chidiac and Nassar (Dany, Chidiac and Nassar, 2015). 
One the major reason to use already existing questionnaire is that it has already been 
implemented and therefore was tested (Hyman, Lamb and Bulmer, 2006). Secondly, it requires 
less time to construct the questionnaire when you have already existing template. Thirdly, in the 
existing questionnaire, conceptualization and measurement of the variables is already done 
(Hyman, Lamb and Bulmer, 2006).  
However, limitations of using the pre-existing questions were also taken into account. As 
some of the questions were not exhaustive they were either deleted or changed to be adapted to 
this study. Moreover, the questionnaire was translated into Kazakh and Russian languages. In 
order to meet the aims of the study, questions on sexual life and lifestyle characteristics were 
added. 
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The questionnaire consisted from 47 items and covered five major topics: social and 
demographic characteristics of the students, questions on awareness about physical health 
problems, questions on knowledge of HPV and HPV vaccination, questions on attitudes towards 
HPV vaccination and HPV infection, and behavioral characteristics of the participants (see the 
questionnaire in the appendix). 
The first section of the questionnaire contained only multiple choice questions which 
asked the participants about their social and demographic characteristics such as age, gender, 
nationality, level of study, study major, and perceived economic status and academic 
performance. The second section contained Yes/No, multiple choice, and open ended questions 
to ask the respondents about their current health status, youth health problems, and reasons for 
health problems, awareness about HPV and HPV vaccination, and sources they heard about HPV 
vaccination. Open ended questions were not mandatory to be answered but were used as a 
thought provocative tool used to prepare students to answer the questions in the next sections.  
The third and the fourth sections were considered as the most important sections as they 
contained the questions about knowledge of HPV and HPV vaccination, attitudes towards HPV 
vaccination, and intention score to receive vaccination. Both of these sections were adopted from 
similar study conducted in Lebanon (Dany, Chidiac and Nassar, 2015). The section of 
knowledge score included 12 True or False knowledge statements about HPV infection or HPV 
vaccine. The next section included 12 statements with 5 point Likert scale: Strongly agree, 
Agree, Neither agree not disagree, Disagree, Strongly disagree which assessed respondents’ 
attitudes towards HPV vaccine. The fourth section also included one question with a 10 point 
scale on how much the student is ready to uptake HPV vaccine, where 1 stood for least likely 
willingness and 10 for most likely willingness to receive the vaccine.  
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The last section contained the most sensitive questions and asked students about their 
behavioral characteristics such as presence of sexual life, presence of sexual partner, method of 
contraception, presence of sexually transmitted infection, test for STI, maintenance of healthy 
diet, smoking status and alcohol consumption. In this section, there were both Yes/No and 
multiple choice questions.  
The questionnaire was conducted in Russian, Kazakh, and in English languages 
depending on the request and study language of the participants.  
           2.6 Pilot study 
In order to validate and to finalize the questionnaire, a pilot study was conducted. All 
three language versions of the questionnaire were tested by 23 students from Eurasian National 
University and Nazarbayev University between October and November 2017. One of the major 
reasons to conduct a pilot study is that it might provide advance warning about where the main 
research study could fail, where research protocols may not be followed, or whether proposed 
methods or instruments are inappropriate or too difficult (van Teijlingen and Hundley, 2001).  
           2.7 Data collection 
Paper-based survey was done in order to obtain data for this study. The data was 
collected between January and February 2018. It took about 15 minute for each participant to 
complete the questionnaire. None of the participants refused to answer or stopped answering at 
any point of the survey.  
3. Ethical Considerations 
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This study design and the content of the questionnaire were approved by Nazarbayev 
University School of Medicine Research Ethical Committee (NUSOM REC). In order to ensure 
that all ethical considerations were taken into account, verbal consent was received from the 
participants. All the participants were familiarized with the study topic and goals. Moreover, 
thorough description of study risks and benefits was given for the participants.  
4. Data analysis 
             4.1 Data entry and data cleaning  
 After the first week of survey administration of the questionnaire, collected data was 
entered into database in the Microsoft Excel software. Database template (codebook) was 
prepared with all of the variables of the study in advance. Data entry proceeded in three weeks in 
February 2018.  
Next step after data entry involved the procedure of cleaning of raw data. This procedure 
was completed to ensure that data was entered correctly and there is no inconsistency. Moreover, 
this step was also important for the analysis part. 
            4.2 Statistical Analysis 
The following step involved the actual data analysis. Data was analyzed using STATA 
13. Data analysis consisted from descriptive statistics including frequencies and mean scores for 
the demographic variables. Data was presented as mean (SD) for continuous variables, and as 
frequency and percentage for categorical variables. Moreover, in order to learn more about the 
relationship between several independent variables and three dependent variable, multivariate 
logistic regression was used. Odds ratios, confidence intervals, and significance value were 
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defined by the software in order to show the association between independent and dependent 
variables.  
Based on the students’ answers to the questionnaire three score were calculated three 
scores: knowledge score, attitude score, and intention score. 
4.2.1 Knowledge score 
The knowledge score was identified using responses of the participants to 12 knowledge 
statements. As knowledge score was categorical variable, mean value was found and was 
considered as a cutoff point. Correct answers to the statements were categorized as 1, all 
incorrect and “Do not know” answers were categorized as 0. Knowledge score lower than mean 
value was considered to be low score, and knowledge score higher than mean value, was 
considered to be high score. High knowledge score meant that student was more knowledgeable 
regarding HPV infection and HPV vaccination in comparison with students with low score. 
4.2.2 Attitude score 
Similar to knowledge score, attitude score was identified using the students’ responses to 
the 12 statements with 5-point Likert scale. In the case of attitude score, mean value was 
considered to be a threshold level. Answers such as “Strongly agree” and “Agree” were 
categorized as 1, and the rest three options which were “Neither agree nor disagree”, 
“Disagree”, and “Strongly Disagree” were categorized as 0. If the student had a total attitude 
score that was higher than mean value, the higher was his attitudes towards HPV vaccination, 
and the same rule was applied for attitude scores lower than threshold level. Higher attitude 
score meant that participants had more positive attitude in comparison with students with low 
attitude score.  
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4.2.3 Intention score 
This score reflecting readiness of the participant to undertake the vaccine was measured 
with one question and was measured on a 10 point scale. First mean value was identified for this 
variable. After that, answers of the participants were categorized. Score lower than mean was 
considered to be low willingness, and score higher than mean was associated with higher 
willingness respectively. The higher the score, the higher intention had the participant to receive 
the vaccination.  
5. Results 
5.1 Participant’s characteristics 
In total, 982 students participated in the study. A summary of the baseline demographics 
and characteristics of the study participants is provided in Table 1. The mean age of the 
participants was 19.9 years (SD±2.3), with 55.1% of the participants aged between 18 and 21 
years. The majority of the students who participated in the study identified themselves as females 
(69.6%) and as representatives of Kazakh (95.4%) nationality. In terms of level of study, more 
than half of the respondents studied at undergraduate level (84.2%), with 38.5% of the 
participants enrolled at 1
st
 year of study. 256 (65.3%) participants identified themselves as 
having good academic performance and 149 (38%) of them were enrolled in health related 
majors, with correspondingly 243 (62%) students enrolled in non-health related majors. The 
majority of the participants perceived their family income as middle (79%) and their health status 
as good (60%).  
More than half of the respondents did not have sexual life (75.5%). Among the 
participants who had sexual life (24.5%), 36.5% were in a committed relationship and 71.1 % 
used condoms as a way of contraception (Table 2).  
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Most of the students (96.2%) never had sexually transmitted infections and only 51 (13%) 
of them had tested themselves for sexually transmitted infection. In terms of relation to healthy 
lifestyle, 246 (62.8%) reported that they maintain a healthy diet, 349 (89%) do not smoke 
cigarettes, and 288 (73.5%) of the respondents do not consume alcohol (Table 3).  
5.2 Sources of information about HPV vaccine 
Before participating in this study 203 (51.8%) students were familiar with HPV and145 
(37%) students heard about HPV vaccination. Table 2 shows the distribution of sources of 
information on HPV vaccine among the participants. University lectures or professor were the 
main source of information for those students who answered that they heard about HPV 
vaccination (Table 4). 
5.3 Knowledge of HPV infection and vaccination 
About half of the respondent students knew HPV transmission routes (43.8%), the fact 
that there are different types of HPV, and whether HPV can lead to genital warts (40.6%) and 
that there are different types of HPV (49%). However, 57.9% did not know that HPV does not 
cause herpes, and 53.3% of the participants did not know that not only women can be infected 
with HPV and show symptoms. Moreover, about one fourth of the participants (25.8%) knew 
that in most cases infected women do not show symptoms. The fact that HPV can be transmitted 
from a carrier to his/her partner not only if the carrier shows symptoms was also unfamiliar facts 
for the students, as a result only 29.9% answered the question correctly. More than half of the 
participants of the survey did not know about the fact that HPV can cause cervical cancer 
(60.2%) and not all HPV types can cause cervical cancer (69.4%) (Table 5).  
Regarding the statements about HPV vaccine, the majority of the participants did not 
know the right answers to the statements. N=267 (68.1%) did not know that the statement that 
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HPV vaccines have the same effect whether the female receive vaccination before or after being 
infected with HPV is false. N=258 (65.8%) did not know that HPV vaccine is best taken before 
the start of sexual activities. Accordingly 66.6% of the students did not know the answer to the 
statement that HPV vaccine can only be taken after the age of 18 years (Table 5). 
Taking into consideration that outcome variables of this study are categorical, 
statistically, the mean knowledge score was 2.20±2.10 (out of 12). This score was also identified 
as a threshold level. Knowledge scores less than mean values were identified as low level of 
knowledge, and correspondingly score higher than 2.20 were identified as high level of 
knowledge. Out of total number of the participants, N=161 (41%) had high level of knowledge. 
As a result of bivariate chi squared test, variables such as gender, academic performance, STI, 
diet, smoking status were found not statistically significantly associated with the level of 
knowledge. The rest of the variables were found associated with the score of knowledge about 
HPV and HPV vaccination (Table 6). 
5.4 Attitudes towards HPV vaccination 
The majority of the participants did not believe that they have increased risk for HPV 
infection (61.7%). About half of the respondents are neutral about the fact that Kazakhstani 
students have a high risk for HPV (47.7%) and that they should receive HPV vaccination 
(45.2%). Adversely, majority of the participants of the study believe that contracting HPV is 
serious (63.8%) and can be life threatening (56.6%). Although 61.8 % of the respondents believe 
that there is a vaccine to prevent HPV, only 23.7 % of the students agree that they would benefit 
from getting the vaccine. Accordingly, moderate number of students believes that HPV vaccine 
is capable of preventing the occurrence of cervical cancer (31.1%), that side effects of the 
vaccine are reasonable (28.1%) and that these side effects will not deter them from taking the 
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vaccine (24%). Majority of the students neither agreed nor disagreed that gynecologists should 
recommend the vaccine to their patients (45.6 %) and they themselves should recommend this 
vaccine for their female friends (58.2 %) (Table 7).  
The mean attitude score in this study was 3.72±2.96. This score was also identified as a 
threshold level. Attitude scores less than mean values were identified as negative attitude, and 
correspondingly scores higher than 3.72 were identified positive attitude. Unlike knowledge 
score, attitude score was only statistically significantly associated with three variables: heard 
about HPV, heard about HPV vaccine, and smoking status (Table 8). 
5.5 Intention to receive HPV vaccination 
The mean intention score is 3.71±2.75 out of 10 (Table 10). Accordingly students with 
intention score that was more than 3 are at most willing to receive HPV vaccine and students 
with intention score less than 3 are at least willing to receive HPV vaccine. Among the students 
who have intention score of 5, there are 21 % of students who were willing to receive HPV 
vaccine. There are only 4.9% of the participants who were willing to receive the vaccine at 
highest intention score. However, there are more students had the least intention score equal to 1 
to receive the vaccine (39%) (Table 9).  
Chi squared test of intention score to receive HPV vaccination with independent 
variables, showed that there are mostly statistically significant associations. Similarly to the case 
of previous dependent variables, gender was not associated with intention score to receive 
vaccination. Moreover, family income was also not statistically significantly associated with 
intention score. Apart from that associations with life style characteristics such as diet and 
smoking status were found to have p value greater than significance value (0.05) (Table 10). 
5.6 Multivariate logistic regression 
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 As a result of bivariate logistic regression, crude odds ratios were obtained. Independent 
variables that were previously statistically associated with dependent variables in chi-squared 
test were added to the model. As a result given crude odds ratios almost all of the independent 
variables are statistically significant predictors for the knowledge score, the exception is the year 
of study (Table 11). In case of attitude score, smoking status of the student, whether he heard 
about HPV and HPV vaccine is a statistically significant predictor (Table 12). And for the last 
dependent variable, all of the independent variables, except for year of study and income level 
were found as statistically significant predictor variables for intention score to receive 
vaccination (Table 13). 
 Based on the outcome of the bivariate logistics regression, multivariate logistic regression 
was performed.  This time as there was controlling for confounding, adjusted odds ratios were 
obtained. As a result of multivariate logistic regression less predictor variable were found to be 
statistically significantly associated with knowledge score, attitude score and intention score. 
From Table 14, variables such as age, family income, whether the student heard about HPV and 
HPV vaccine, and alcohol consumption were found as significant predictors of the knowledge 
score. According to Table 15, only whether the student heard about HPV before the study was 
statistically associated with attitudes towards HPV vaccination. In the last table, Table 16, 
intention score to receive HPV vaccination is only statistically associated with academic 
performance of the student, whether the student heard about HPV and HPV vaccination prior to 
the study, or whether the student uses contraception.  
 
6. Discussion 
 Current study aimed to identify the association between students’ knowledge of HPV, 
attitudes towards HPV vaccination and intention score to receive the vaccine and various socio-
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demographic characteristics of Astana students. Several socio demographic variables were found 
to statistically significantly predict the outcome variables. 
Out of approached 392 people, all of them gave the consent to participate in the study and 
no one withdrawn during the process of survey. Therefore, response rate can be considered to be 
100%.  According to Fincham response rate approximating 60%  should be the goals of 
researchers (Fincham, 2008). Moreover, 60% is the minimum level that is required by certain 
biomedical journals (Livingston and Wislar, 2012). Therefore this number of participants can be 
considered as enough to represent the total population of Astana students. Considering this it can 
be assumed the bias of non-response rate is not present in this study. However, response rate 
cannot be the only factors during the assessment of survey quality and bias (Livingston and 
Wislar, 2012). 
To discuss the awareness about HPV, about half of the students heard about HPV 
infection and only one third of them heard about HPV vaccination before participating in this 
study. The major source from which students heard about vaccine was university lecture or 
university professor (37%). However, another study showed that in terms of distribution of 
source of information on HPV vaccination program, friend was the major source of information 
about HPV (Shafei et al., 2014). The previous study had also the same trend with current study 
as more students were aware about HPV infection and less students were aware about HPV 
vaccination(Shafei et al., 2014). 
 This study was the first cross sectional study in Kazakhstan on the topic of HPV and 
HPV vaccination that used the framework of knowledge, attitude, and practice. Moreover, this 
study quantitatively examined the knowledge and behavioral perception of students. The results 
of this study revealed that more than half of the respondents had low level knowledge of HPV 
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infection. However, despite the low scores of knowledge, half of the students had positive 
attitudes towards HPV vaccination and were willing to receive HPV vaccination was also high.  
The results from previous studies conducted abroad also demonstrate low level of 
knowledge of HPV among students. The findings are similar to the study by Dany, Chidiac and 
Nassar (Dany, Chidiac and Nassar, 2015), whereby despite low to moderate score of knowledge 
of HPV, there were high scores attitudes towards vaccination and intention score to receive the 
vaccine (Sherman et al., 2016). Similar study conducted in Nigeria revealed that only 17.7% of 
female students were aware of HPV (Makwe, Anorlu and Odeyemi, 2012). In addition, a study 
conducted in England demonstrated that despite being aware of HPV only 27% of the 
respondents knew that HPV causes cervical cancer. Therefore, findings from this study and from 
previous studies reveal that there is inadequate knowledge of HPV irrespective of the country.  
 Such relatively low knowledge of HPV infection can be related to several factors that are 
peculiar to Kazakhstan. First of all at the university level, only students who are studying health 
related majors have access to courses that can touch upon the topic of HPV, unlike students 
studying other majors. At the school level, the topic of HPV is not included in the study 
curriculum. Secondly, HPV vaccination program was introduced relatively recently and it has 
not been popularized among the population. Moreover, the target population of vaccination 
program is primarily youth who have not yet started their sexual life.  
 From a bivariate analysis, this study revealed that students pursuing health majors are 
more knowledgeable about HPV and HPV infection. 98 out of 149 students studying health 
majors such as pharmacy, public health, and medicine, and only 63 out of 243 students studying 
non health related major had high knowledge score. However, similar study conducted among 
medical students in Malaysia revealed that being medical student does not necessarily guarantee 
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good perception and knowledge of HPV infection and vaccination (Shafei et al., 2014). 
Moreover, that study also found that medical students at the last years of program are more 
knowledgeable in comparison with students studying at earlier years (Shafei et al., 2014). These 
findings point out to the fact that HPV related topics are covered in a later period of the study. 
Therefore, future studies should take into account this fact and search for associations between 
study curriculum and knowledge of students about HPV.  
 About half of the participants of the study had positive attitudes towards HPV 
vaccination and high intention score to receive HPV vaccination. The reason why only half of 
the participants have good perception of vaccine and are ready to receive it can be explained by 
the fact that HPV is a sexually transmitted infection and therefore represents a potential barrier to 
acceptance of the vaccine as the vaccine should be administered prior to the first sexual contact 
(Cavazos-Rehg et al., 2009). According to the study conducted in 1991, median age at first sex 
for the cohort born between 1970 and 1974 was 23.7 for males and 20.7 for females in 
Kazakhstan (Bruni et al., 2017). The finding of the study can be applicable to this study as mean 
age of the participants was 19.9 and 24.5% of the respondents already had sexual life. Therefore, 
by default one fourth of the participants were not suitable for vaccination, as they already have 
had their first sexual contact.  
7. Study Limitations 
Despite that this study has focused on under-researched topic, has sufficient sample size, 
and can serve as a baseline for further studies, there are certain limitations. First of all this is 
a cross sectional study. Consequently any inferences about cause and effect cannot be drawn 
from this study. Second limitation is that study instrument was a self-reported questionnaire 
and therefore the data could be underreported. The third limitation of this study is about 
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selection bias. As it was mentioned earlier one of the sampling techniques was non random 
sampling within universities during selection of students.  
8. Study implications and further recommendations 
In conclusion, this cross sectional study has focused on the topic of knowledge of HPV 
infection and perception of HPV vaccination which included attitudes towards and intention 
to receive the vaccine among Astana students. The study was conducted among 4 Astana 
universities and included 392 participants aged between 16 and 30 years. Overall, this study 
revealed low level of knowledge among the majority of students. In contrast there were more 
students with high attitude score to the vaccine and high intention score to receive the 
vaccine. Moreover, multivariate logistic regression demonstrated several sociodemographic 
and behavioral characteristics were statistically significantly associated with knowledge, 
attitude, and intention score. The results of current study are consistent with previous studies. 
Implications of this study can be twofold. On the one hand this study could contribute to 
the improvement of the existing vaccination policy in Kazakhstan. Results of this study 
might suggest that not only school children but also students need to be addressed by the 
vaccination policy. On the other hand this study could provide the suggestions for 
vaccination policy. Current study revealed significant knowledge gaps among the students 
about HPV infection and vaccination. Therefore, authorities should target students and 
introduce the changes into study curriculum that will enhance their knowledge about HPV 
infection and vaccination.  
In order to improve upon the current study, further recommendations can be provided. 
First of all in order to make the study generalizable to the whole population of Kazakhstan, 
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the scale of this study should be expanded to the national scale. Secondly, in order to keep 
track the changes in terms of knowledge about HPV and perception of HPV prevention, the 
design of the study should be changed from cross sectional to longitudinal panel study. 
Thirdly, in order to provide evidence based recommendations for introduction of policy 
changes, it is important to conduct thorough policy analysis as well as the effectiveness of 
policy interventions.   
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Appendix 1. Tables 
Table 1 
Baseline demographics and characteristics of the participants. 
Variable n (%) Mean SD Range 
Number of participants  392 (100%)    
Age (years)  19.9 2.3 16-30 
<18 40 (10.2%)    
18-<21 216 (55.1%)    
>=21 136 (34.7%)    
Gender     
Male 119 (30.4%)    
Female 273 (69.6%)    
Ethnicity     
Kazakh  374 (95.4%)    
Other 18 (4.6%)    
Year of study     
1
st
 year undergraduate 151 (38.5%)    
2
nd
 year undergraduate 97 (24.7%)    
3
rd
 year undergraduate 20 (5.1%)    
4
th
 year undergraduate 36 (9.2%)    
5
th
 year undergraduate 26(6.7%)    
Graduate 62(15.8%)    
Level of study     
Undergraduate 330 (84.2 %)    
Graduate  62 (15.8 %)    
Major     
Arts 4 (1 %)    
Engineering 21 (5.4%)    
Humanities 65 (16.6%)    
Law 1 (0.3%)    
Maths and Physics 24 (6.1%)    
Medicine 81 (20.7%)    
Natural Sciences 48 (12.2%) 
Pharmacy 16(4.1%)    
Public Health 52 (13.3%)    
Social Sciences 30(7.6%)    
Other 50 (12.7)    
Major type     
Health-related 149 (38%)    
Non-health related 243(62%)    
Academic Performance     
Excellent 107 (27.3%)    
Good 256 (65.3%)    
Satisfactory 29 (7.4%)    
Family income     
High income 36 (9.2%)    
Middle income 310 (79%)    
Low income 36 (9.2%)    
Other 10 (2.6%)    
Health status     
Excellent 102 (26%)    
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Good 236 (60%)    
Satisfactory 5 (1%)    
Bad 49 (13%)    
Table 2 
Description of participants’ sexual life 
Variable n(%) 
Sexual Life 
Yes 
 
96 (24.5%) 
No 296 (75.5%) 
Sexual Partner 96 (100%) 
Yes, I am in a committed 
relationship 
35 (36.5%) 
Yes, I am married 13 (13.5%) 
Yes, but I am not limited to 
only one sexual partner 
15 (15.6%) 
No 33 (34.4%) 
Contraception type 96 (100%) 
I do not use 16 (16.7 %) 
Condoms 74 (77.1%) 
Birth control pills 3 (3.1%) 
Other 3 (3.1%) 
Table 3 
Participant’s lifestyle and behavioral characteristics  
Variable n (%) 
STI  
Yes 15 (3.8%) 
No 377 (96.2%) 
Test STI  
Yes 51 (13%) 
No 341 (87%) 
Diet  
Yes 246 (62.8%) 
No 146 (37.2%) 
Smoking status  
More than 10 cigarettes daily 2 (0.5%) 
6-10 cigarettes daily 6 (1.5%) 
1-5 cigarettes daily 35 (9%) 
I do not smoke 349 (89%) 
Alcohol consumption  
3-7 times a week 4 (1%) 
Once a week 10 (2.6%) 
Only on weekends and special 
occasions 
90 (23%) 
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I do not consume alcohol 288 (73.5%) 
Table 4 
Participants’ awareness about HPV and HPV vaccination and sources of information about HPV 
vaccine 
 
Variable n (%) 
Heard about HPV    
Yes 203 (51.8%) 
No 189 (48.2%) 
Heard about HPV vaccine  
Yes 145 (37%) 
No 247 (63%) 
Source heard about HPV vaccine  145 (100%) 
University lectures or professor   49 (33.8%) 
Internet   30 (20.7%) 
Media   27 (18.6%) 
Friends   6 (4.1%) 
Family   4 (2.8 %) 
Other   17 (11.7%) 
Table 5 
Participants’ answers to knowledge statements about human papillomavirus and its vaccination. 
Knowledge statement Correct  
answer 
True  
n (%) 
False  
n (%) 
Do not  
know  
n (%) 
HPV can be transmitted through vaginal, anal, and oral 
sex as well as genital to genital contact  
 
True 172 
(43.8 %) 
14 
(3.6 %) 
206 
(52.6 %) 
Human papillomavirus can lead to genital warts (growths 
on the skin of the genitals)  
 
True 159 
(40.6 %) 
15 
(3.8 %) 
218 
(55.6 %) 
Human papillomavirus can cause herpes  
 
False 113 
(28.8 %) 
52  
(13.3 %) 
227 
(57.9 %) 
There are different types of HPV  
 
True 192  
(49 %) 
6 
(1.5 %) 
194 
(49.5 %) 
HPV can cause cervical cancer  
 
True 141 
(36 %) 
15 
(3.8 %) 
236 
(60.2 %) 
All HPV types can cause cervical cancer  
 
False 35  
(8.9 %) 
85  
(21.7 %) 
272 
(69.4 %) 
Only females can be infected with HPV and show 
symptoms  
 
False 41 
(10.5 %) 
142 
(36.2 %) 
209 
(53.3 %) 
In most cases, HPV infected women do not show 
symptoms 
True 101 
(25.8 %) 
49 
(12.5 %) 
242 
(64.7 %) 
HPV can be transmitted from a carrier to his/her partner 
only if the carrier shows symptoms  
 
False 57  
(14.6 %) 
 
 
117  
(29.9 %) 
217 
(55.5 %) 
HPV vaccines have the same effect whether the female 
receive vaccination before or after being infected with 
HPV  
False 38 
(9.7 %) 
87 
(22.2 %) 
267 
(68.1 %) 
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HPV vaccine is best taken before the start of sexual 
activities  
 
True 113 
(28.8 %) 
21 
(5.4 %) 
258 
(65.8 %) 
HPV vaccine can only be taken after the age of 18 years  
 
False 44 
(11.2 %) 
87 
(22.2 %) 
261 
(66.6 %) 
 
Table 6.  
Participants’ knowledge score on HPV and HPV vaccination statements stratified by 
participants’ characteristics. 
 
Variable Knowledge p-Value mean ± SD 
High n (%) Low n (%)   
All  
Participants 
161 (41%) 231 (59%)  2.20±2.10 
Age   p=0.000*  
<21 57 (22.3%) 199 (77.7%)   
≥21 104 (76.5%) 32 (23.5%)   
Gender  p=0.112  
Male 56 (47.1 %) 63 (52.9 %)   
Female 105 (38.5 %) 168 (61.5 %)   
Year of study  p= 0.000*  
1st year 33 (21.8%) 118 (75.2 %)   
2nd year 24 (24.7%) 73 (75.3%)   
3rd year 5 (25 %) 15 (75 %)   
4th year 25 (69.4 %) 11 (30.6 %)   
5th year 22 (84.6 %) 4 (15.4 %)   
Graduate 57 (91.9 %) 5 (8.1%)   
Level of study  p= 0.000*  
Undergraduate 104 (31.5 %) 226 (68.5 %)   
Graduate 57 (91.9 %)  5 (8.1%)   
Major type   p= 0.000*  
Health-related 98 (65.8 %) 51 (34.2%)   
Non-health related 63 (25.9%) 180 (74.1%)   
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Academic performance  p=0.497  
Excellent 41 (38.3%) 66 (61.7 %)   
Good+ Satisfactory 120 (42.1 %) 165 (57.9 %)   
Income  p =0.005*  
High income 10 (27.8%) 26 (72.2%)   
Middle income 128 (40%) 192 (60%)   
Low income 23 (63.9%) 13 (36.1%)   
Heard about HPV   p= 0.000*  
Yes 131 (64.5 %) 72 (35.5 %)   
No 30 (15.9 %) 139 (84.1%)   
Heard about HPV 
vaccine 
 p= 0.000*  
Yes 105 (72.4 %) 40 (27.6 %)   
No 56 (22.7 %) 191 (77.3 %)   
Sexual life  p=0.003*  
Yes 44 (45.8 %) 52 (54.2%)   
No 149 (50.3 %) 147 (49.7%)   
Sexual partner 
 
 p= 0.011*  
Yes 35 (55.6%) 28 (44.4%)   
No 126 (38.3%) 203 (61.7%)   
Contraception  p= 0.010*  
 Yes 41 (53.3%) 36 (46.7%)   
No 120 (38.1%) 195 (61.9%)   
STI 
 
 p= 0.129  
Yes 9 (60%) 6 (40%)   
No 152 (40.3%) 225 (59.7 %)   
Test STI  p= 0.000*  
Yes 39 (76.5 %) 12 (23.5 %)   
No 122 (35.8 %) 219 (64.2%)   
Diet  p=0.205  
Yes 107 (43.5%) 139 (56.5%)   
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* Ch-square test, signifies p value <0.05 
Table 7 
Participants’ attitudes towards HPV vaccination statements. 
Attitude assessing 
statement 
Strongly agree 
n (%) 
Agree n (%) Neither agree 
nor disagree n 
(%) 
Disagree n (%) Strongly 
disagree n (%) 
Based on my lifestyle, 
I believe that I have 
increased risk for the 
HPV infection  
 
19 
(7.9 %) 
31 
(7.9 %) 
100 
(25.5 %) 
126 
(32.1 %) 
116 
(29.6 %) 
I believe that there is a 
vaccine to prevent 
HPV  
 
81 
(20.7 %) 
161 
(41.1 %) 
127 
(32.4 %) 
12 
(3.0  %) 
11 
(2.8 %) 
Based on my lifestyle, 
I believe that I would 
benefit from getting 
the vaccine  
 
24 
(6.1 %) 
69 
(17.6 %) 
190 
(48.5 %) 
73 
(18.6 %) 
36 
(9.2 %) 
I believe that 
Kazakhstani students 
have a good chance of 
contracting HPV  
 
31 
(7.9 %) 
89 
(22.7 %) 
187 
(47.7 %) 
67 
(17.1 %) 
18 
(4.6 %) 
I believe that 
Kazakhstani students 
should receive the 
HPV vaccine  
 
57 
(14.5 %) 
123 
(31.4 %) 
177 
(45.2 %) 
22 
(5.6 %) 
13 
(3.3 %) 
I believe that 
contracting HPV virus 
is serious  
 
94 
(24 %) 
156 
(39.8 %) 
121 
(30.9 %) 
12 
(3.0 %) 
9 
(2.3 %) 
I believe that 
contracting HPV can 
be life threatening  
 
92 
(23.5 %) 
130 
(33.1 %) 
140 
(35.7 %) 
21 
(5.4 %) 
9  
(2.3 %) 
I believe that the 36  86 235  24  11 
No 54 (37%) 92 (63%)   
Smoking status  p= 0.442  
Yes 141 (40.4%) 20 (46.5%)   
No 208 (59.6 %) 23 (53.5%)   
Alcohol consumption  p= 0.000*  
Yes 189 (65.6%) 42 (40.4%)   
No 99 (34.4%) 62 (59.6%)   
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current HPV vaccine is 
capable of preventing 
the occurrence of 
cervical cancer.  
 
(9.2 %) (21.9 %) (60.0 %) (6.1 %) (2.8 %) 
I believe that the side 
effects of the vaccine 
are reasonable  
 
27 
(6.9 %) 
83 
( 21.2 %) 
236 
(60.2 %) 
34 
(8.7 %) 
12 
(3.0 %) 
I believe that the side 
effects of the vaccine 
will not deter me from 
taking the vaccine.  
 
34 
(8.7 %) 
63 
(16.1 %) 
237 
(60.4 %) 
43 
(11 %) 
15 
(3.8 %) 
I believe that all 
gynecologists should 
recommend the 
vaccine to their 
patients  
 
55 
(14.0 %) 
116 
(29.6 %) 
179 
(45.6 %) 
32 
(8.2 %) 
10 
(2.6 %) 
I would recommend 
this vaccine for my 
female friends  
 
42 
(10.7 %) 
76 
(19.4 %) 
288 
(58.2 %) 
31 
(7.9 %) 
15 
(3.8 %) 
 
Table 8 
Participants’ attitude score on HPV vaccination statements stratified by participants’ 
characteristics. 
Variable Attitude p-Value mean ± SD 
 Positive Negative   
All  
Participants 
193 
(49%) 
199 
(51%) 
 3.72±2.96 
Age   p=0.200  
-<21 120 (46.9%) 136 (53.1%)   
>=21 73 (53.7%) 63 (46.3%)   
Gender  p= 0.928  
Male 59 (49.6%) 60 (50.4%)   
Female 134 (49.1%) 139 (50.9%)   
Year of study  p=0.199  
1st year 70 (36.3%) 81 (53.6%)   
2nd year 48 (49.5%) 49 (50.5%)   
3rd year 8 (40%) 12 (60%)   
4th year 21 (58.3%) 15 (41.7%)   
5th year 9 (34.6%) 17 (65.4%)   
Graduate 37 (59.7%) 25 (40.3%)   
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Level of study  p=0.073  
Undergraduate 156 (47.3%) 174 (52.73%)   
Graduate 37 (59.68%) 25 (40.32%)   
Major type   p=0.240  
Health-related 114 (46.9 %) 46 (30.9 %)   
Non-health related 129 (53.1 %) 97 (39.9 %)   
Academic performance  p=0.288  
Excellent 48 (44.9%) 59 (55.77%)   
Good+ Satisfactory 145 (50.9%) 140 (49.12%)   
Income  p=0.193  
High income 17 (47.22%)                19 (52.78%)   
Middle income 162 (50.63%)               158 (49.38%)   
Low income 14 (38.89%)                 22 (61.11%)   
    
Heard about HPV   p=  0.015*  
Yes 112 (55.2%) 91 (44.8%)   
No 81 (42.9%) 108 (57.1%)   
Heard about HPV 
vaccine 
 
 p=  0.008*  
Yes 84 (57.9%) 61 (42.1%)   
No 109 (44.1%) 138 (55.9%)   
Sexual life 
 
 p=  0.443  
Yes 44 (45.8%) 52 (54.2%)   
No 149 (50.3%) 147 (49.7%)   
Sexual partner  p= 0.167  
Yes 26 (41.3%) 37 (58.7%)   
No 167 (50.8%) 162 (49.2%)   
Contraception  p= 0.782  
 Yes 39 (50.7%) 38 (49.4%)   
No 154 (48.9%) 161 (51.1%)   
STI 
 
  p=  0.746  
Yes 8 (53.3 %) 7 (46.7 %)   
No 185(49.1%) 192 (50.9%)   
Test STI   p=  0.570  
Yes 166 (48.7%) 27 (52.9%)   
No 175 (51.3%) 24 (47.1%)   
Diet  p=0.417  
Yes 125 (50.8%) 121 (49.2%)   
No 68 (46.6%) 78 (53.4%)   
Smoking status 
 
 p=  0.003*  
Yes 12 (27.9%) 31 (72.1%)   
No 181 (93.8%) 168 (48.1%)   
Alcohol consumption   p=  0.385  
Yes 55 (52.9%) 49 (47.1%)   
No 138 (47.9%) 150 (52.1%)   
* Ch-square test, signifies p value <0.05 
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Table 9 
Participants’ intention score to receive HPV vaccination. 
Intention score  n (%) 
1 153(39 %) 
2 16 (4.1 %) 
3 31 (7.9 %) 
4 26 (6.6 %) 
5 81 (21 %) 
6 20 (5.1 %) 
7 22 (5.6 %) 
8 13 (3.3 %) 
9 11 (2.8 %) 
10 19 (4.9 %) 
 
Table 10 
Participants’ intention score to receive HPV vaccination stratified by participants’ 
characteristics. 
Variable Intention score p-Value mean ± SD 
High Low   
All  
Participants 
192 
(49%) 
200 
(51%) 
 3.71±2.75 
Age   p = 0.000*  
-<21 95 (69.9%) 41 (30.1%)   
>=21 97 (37.9%) 159 (62.1%)   
Gender  p=0.778  
Male 135 (49.5%)  138 (50.5%)    
Female 57 (47.9%) 62 (52.1%)   
Year of study  p= 0.000*  
1st year 54 (35.8%) 97 (64.2%)   
2nd year 45 (46.4%) 52 (53.6%)   
3rd year 6 (30%) 14 (70%)   
4th year 24 (66.7%) 12 (33.3%)   
5th year 13 (50%) 13 (50%)   
Graduate 50 (80.7%) 12 (19.3%)   
Level of study  p= 0.000*  
Undergraduate 50 (80.7%)  12 (19.3%)    
Graduate 142 (43%) 188 (57%)   
Major type  p=0.001*  
Health-related 89 (59.7%) 60 (40.3%)   
Non-health 
related 
140 (57.6%) 103 (42.4%)   
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Academic 
performance 
 p= 0.018*  
Excellent 42 (39.3 %) 65 (60.7%)   
Good+ 
Satisfactory 
150 (52.6%) 135 (47.4%)   
Income  p=0.446  
High income 14 (38.89%)         22 (61.11%)   
Middle income 160 (50%)            160 (50%)                     
Low income 18 (50%)              18 (50%)                    
Heard about 
HPV  
 p= 0.000*  
Yes 132 (65%) 71 (35%)   
No 60 (31.8%) 129 (68.2%)   
Heard about 
HPV vaccine 
  p=  0.000*  
Yes 88 (60.7%) 57 (39.3%)   
No 143 (48.11%) 104 (57.89%)   
Sexual life  p=  0.000*  
Yes 64 (66.7%) 32 (33.3%)   
No 128 (43.2%) 168 (56.8%)   
Sexual partner  p=  0.002*  
Yes 42 (66.7%) 21 (33.3%)   
No 150 (45.6%) 179 (54.4%)   
Contraception  p=0.000*  
 Yes 53 (68.8%) 24 (31.2%)   
No 139 (44.1%) 176 (55.9%)   
STI  p=  0.014*  
Yes 12 (80%) 3 (20%)   
No 180 (47.8%) 197 (52.2%)   
Test STI  p=0.000*  
Yes 40 (78.4%) 11 (21.6%)   
No 152 (44.6%) 189 (55.4%)   
Diet   p=0.915  
Yes 121 (49.2%)  125 (50.8%)   
No 71 (48.6%) 75 (51.4%)   
Smoking status  p=0.531  
Yes 23 (53.5%) 20 (46.5%)   
No 169 (48.4%) 180 (51.6%)   
Alcohol 
consumption 
 p=  0.000*  
Yes 70 (67.3%) 34 (32.7 %)   
No 122 (42.4%) 166 (57.6%)   
* Ch-square test, signifies p value <0.05 
Table 11 
Crude odds ratios of knowledge score on HPV and HPV vaccination statements. 
Variable OR CI p-Value 
Age     
-<21 Ref.   
>=21 11.34 6.93-18.59 0.000* 
Year of study    
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1
st
 year Ref.   
2
nd
 year 1.17 0.64-2.15 0.598 
3
rd
 year 1.19 0.40-3.52 0.751 
4
th
 year 8.13 3.62-18.22 0.000* 
5
th
 year 6.75 2.76-16.54 0.000* 
Graduate 4.76 15.11-109.96 0.000* 
Level of study    
Undergraduate Ref.   
Graduate 24.77 9.64-63.62 0.000* 
Major type    
Health-related 5.49 3.52-8.56 0.000* 
Non-health related Ref.   
Income    
Middle 0.36 0.18-0.73 0.005* 
High+Low Ref.   
Heard about HPV     
Yes 9.64 5.94-15.66 0.000* 
No Ref.   
Heard about HPV vaccine 
 
   
Yes 8.95 5.59-14.33 0.000* 
No Ref.   
Sexual life    
Yes 2.03 1.27-3.23 0.003* 
No Ref.   
Sexual partner    
Yes 2.01 1.17-3.47 0.012* 
No Ref.   
Contraception    
 Yes 1.85 1.12-3.06 0.016* 
No Ref.   
Test STI    
Yes 5.84 2.94-11.56 0.000* 
No Ref.   
Alcohol consumption    
Yes 2.81 1.77-4.47 0.000* 
No Ref.   
 
 
Table 14 
Adjusted odds ratios of knowledge score on HPV and HPV vaccination. 
Variable OR CI p-Value 
Age     
-<21 Ref.   
>=21 3.79 2.43-5.93 0.000* 
Level of study    
Undergraduate Ref.   
Graduate 2.80 0.84-9.25 0.092 
Major type    
Health-related 1.33 0.70-2.53 0.381 
Non-health related Ref.   
Income    
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Middle 0.31 0.13-0.75 0.009* 
High+Low Ref.   
Heard about HPV     
Yes 2.26 1.15-4.45 0.018* 
No Ref.   
Heard about HPV vaccine 
 
   
Yes 2.64 1.35-5.17 0.004* 
No Ref.   
Sexual life    
Yes 1.17 0.27-5.01 0.832 
No Ref.   
Sexual partner    
Yes 0.80 0.24-2.69 0.715 
No Ref.   
Contraception    
 Yes 0.50 0.12-2.19 0.355 
No Ref.   
Test STI    
Yes 1.42 0.54-3.70 0.477 
No Ref.   
Alcohol consumption    
Yes 2.17 1.08-4.33 0.029* 
No Ref.   
 
Table 12 
Crude odds ratios of attitude score on HPV vaccination. 
Variable OR CI p-Value 
Heard about HPV     
Yes 1.64 1.10-2.45 0.015* 
No Ref.   
Heard about HPV vaccine 
 
   
Yes 1.74 1.15-2.64 0.009* 
No Ref.   
Smoking status    
Yes 0.35 0.18-0.72 0.004* 
No Ref.   
 
Table 15 
Adjusted odds ratios of attitude score on HPV vaccination 
Variable OR CI p-Value 
Heard about HPV     
Yes 0.34 0.17-0.69 0.003* 
No Ref.   
Yes 1.54 0.88-2.69 0.134 
No Ref.   
Smoking status    
Yes 0.34 0.74-2.18 0.381 
No Ref.   
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Table 13 
Crude odds ratios of intention score to receive HPV vaccination 
Variable OR CI p-Value 
Age     
-<21 Ref.   
>=21 11.34 6.93-18.59 0.000* 
Year of study    
1
st
 year Ref.   
2
nd
 year 1.55 0.92-2.61 0.096 
3
rd
 year 0.77 0.28-2.12 0.613 
4
th
 year 3.59 1.67-7.75 0.001* 
5
th
 year 1.80 0.78-4.15 0.171 
Graduate 7.48 3.67-15.26 0.000* 
Level of study    
Undergraduate Ref.   
Graduate 5.51 2.83-10.74 0.000* 
Major type    
Health-related 2.02 1.33-3.06 0.001* 
Non-health related Ref.   
Academic Performance    
Excellent 0.58 0.37-0.91 0.019* 
Good+Satisfactory Ref   
Income    
Middle 0.96 0.48-1.90 0.898 
High+Low Ref.   
Heard about HPV     
Yes 4.00 2.62-6.09 0.000* 
No Ref.   
Heard about HPV vaccine 
 
   
Yes 2.12 1.40-3.22 0.000* 
No Ref.   
Sexual life    
Yes 2.63 1.62-4.25 0.000* 
No Ref.   
Sexual partner    
Yes 2.39 1.36-4.21 0.003* 
No Ref.   
Contraception    
Yes 2.80 1.64-4.76 0.000* 
No Ref.   
STI    
Yes 4.38 1.22-15.76 0.024* 
No Ref.   
Test STI    
Yes 4.52 2.24-9.11 0.000* 
No Ref.   
Alcohol consumption    
Yes 2.80 1.74-4.49 0.000* 
No Ref.   
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Table 16 
Adjusted odds ratios of intention score to receive HPV vaccination. 
Variable OR CI p-Value 
Age     
-<21 Ref.   
>=21 1.59 0.84-2.98 0.153 
Level of study    
Undergraduate Ref.   
Graduate 2.21 0.88-5.53 0.090 
Major type    
Health-related 0.81 0.45-1.46 0.480 
Non-health related Ref.   
Academic Performance    
Excellent 0.51 0.31-0.86 0.011* 
Good+Satisfactory Ref   
Income    
Middle 0.96 0.48-1.90 0.898 
High+Low Ref.   
Heard about HPV     
Yes 4.25 2.23-8.11 0.000* 
No Ref.   
Heard about HPV vaccine 
 
   
Yes 0.45 0.23-0.87 0.019* 
No Ref.   
Sexual life    
Yes 1.54 0.46-5.13 0.484 
No Ref.   
Sexual partner    
Yes 0.66 0.23-1.85 0.424 
No Ref.   
Contraception    
 Yes 1.29 1.64-4.76 0.000* 
No Ref.   
STI    
Yes 2.50 0.60-10.43 0.207 
No Ref.   
Test STI    
Yes 1.85 0.79-4.34 0.159 
No Ref.   
Alcohol consumption    
Yes 1.69 0.94-3.01 0.077 
No Ref.   
 
 
 
46 
 
Appendix 3. Questionnaire (English, Kazakh, Russian)                                                                   
Questionnaire 1. English version 
 
Part 1: Social characteristics of the participants  
 
 
Q1. What is your age? ____________ 
 
Q2. What is your gender?  
1. Male 
2. Female 
 
Q3.What is your nationality? 
1. Kazakh 
2. Russian 
3. Other_____________________________ 
 
 
Q4. At what level are you studying now? 
1. 1st year undergraduate 
2. 2nd year undergraduate 
3. 3rd year undergraduate 
4. 4th year undergraduate 
5. 5th year undergraduate 
6. Graduate (including, 6-7 year medical students)  
7. Other (please, specify):___________________ 
 
 Q5. What is the field of your major? 
1. Humanities 
2. Social Sciences 
3. Arts 
4. Law 
5. Engineering  
6. Natural Sciences 
7. Maths and Physics 
8. Medicine 
9. Pharmacy 
10. Public Health 
11. Other:__________________________________ 
 
Q6. How would you assess your academic performance? 
1. Excellent 
2. Good 
3. Satisfactory 
4. Unsatisfactory 
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Q7. What is your perceived economic status? 
1. High income 
2. Middle income 
3. Low income 
4. Other (please specify):______________ 
 
Part 2: Awareness of physical health problems 
 
 
Q8. How would you generally assess your current health status? 
1. Excellent 
2. Good 
3. Satisfactory  
4. Bad 
 
Q9. What do you consider to be major health problems that may be experienced at your age? 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
Q10. What do you consider to be common reasons for getting a disease at your age? 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Q11. Before taking this survey, have you ever heard of HPV (human papillomavirus)? 
1. Yes 
2. No 
 
Q12. Before taking this survey, have you ever heard of HPV vaccine? 
1. Yes 
2. No (go to Q12) 
 
Q13. If «Yes», what was the source that you hear from about the vaccine? 
1. Media (advertisements, TV news, radio ) 
2. Internet 
3. Doctor or Gynecologist 
4. University lectures or Professors 
5. Family 
6. Friends 
7. Others, please specify  
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Part 3: Questions on knowledge of HPV and HPV vaccination 
 
 
      
Please mark only one correct answer in each of the statements 
below 
True 
 
False Do not Know 
(Q14- Q25) 
 
   
Q14. HPV can be transmitted through vaginal, anal, and oral sex 
as well as genital to genital contact 
•   
 
•   •   
Q15. Human papillomavirus can lead to genital warts (growths 
on the skin of the genitals) 
 
•   •   •   
Q16. Human papillomavirus can cause herpes 
 
•   •   •   
Q17. There are different types of HPV •   •   •   
Q18. HPV can cause cervical cancer •   •   •   
Q19. All HPV types can cause cervical cancer •   •   •   
Q20. Only females can be infected with HPV and show 
symptoms 
•   •   •   
Q21. In most cases, HPV infected women do not show 
symptoms 
•   •   •   
Q22. HPV can be transmitted from a carrier to his/her partner 
only if the carrier shows symptoms 
 
•   •   •   
Q23. HPV vaccines have the same effect whether the female 
receive vaccination before or  after being infected with HPV  
•   •   •   
Q24. HPV vaccine is best taken before the start of sexual 
activities 
•   •   •   
Q25. HPV vaccine can only be taken after the age of 18 years 
 
 
•   •   •   
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For the following questions Q26-Q37 please,  
assess your agreement or disagreement with the 
following statements: 
Strongl
y agree 
Agree Neither 
agree nor 
disagree 
Disagre
e 
Strongl
y 
disagre
e 
Q26. Based on my lifestyle, I believe that I have 
increased risk for the HPV infection 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q27. I believe that there is a vaccine to prevent HPV  
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q28. Based on my lifestyle,  I believe that I would 
benefit from getting the vaccine  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q29. I believe that Kazakhstani students have a good 
chance of contracting HPV  
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q30. I believe that Kazakhstani students should 
receive the HPV vaccine 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q31. I believe that contracting HPV virus is serious   
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q32. I believe that contracting HPV can be life 
threatening 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q33. I believe that the current HPV vaccine is 
capable of preventing the occurrence of cervical 
cancer. 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q34. I believe that the side effects of the vaccine are 
reasonable 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Q35. I believe that the side effects of the vaccine will 
not deter me from taking the vaccine. 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Q36. I believe that all gynecologists should 
recommend the vaccine to their patients 
 
     
Q37. I would recommend this vaccine for my female 
friends                                                                                  
                                                                                                 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
 
 
 
 
 
 
□ 
 
□ 
 
□ 
 
Q38. On a scale of 1-10: 1 being least likely and 10 being most likely, how much are you willing 
now to get vaccinated with HPV vaccine ? (Please choose one number) 
Least likely---------------------------------------------------------------------------------->Most likely 
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
Part 4: Questions on attitudes towards HPV vaccination and HPV infection 
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Q39. Do you have a sexual life? 
1. Yes 
2. No 
 
Q40. Do you have a constant sexual partner? 
1. Yes, I am married 
2. Yes, I am in a committed relationship 
3. Yes, but I am not limited to only one sexual partner 
4. No 
 
Q41. What kind of contraception/birth control do you use? 
1. Condoms 
2. Birth Contol pills 
3. Ointments 
4. Spiral 
5. I do not use them 
6. Other (please specify):___________________________________________ 
 
Q42. Have you ever had a sexually transmitted infection (STI) (e.g. HIV, herpes, gonorrhea, 
syphilis, hepatitis B and C)?  
1. Yes 
2. No 
 
Q43. Have you ever had yourself tested for an STI (including an HPV test ?) 
1. Yes 
2. No 
 
Q44. Do you think you maintain a healthy diet? (e.g. you eat a balanced meal of meat, vegetables 
and carbohydrates) 
1. Yes 
2. No 
 
Q45. Do you smoke? 
1. Yes, 1-5 cigarettes daily 
2. Yes, 6-10 cigarettes daily 
3. Yes, more than 10 cigarettes daily 
4. I don’t smoke 
 
Q46. Do you consume alcohol? 
1. Yes, 3-7 times a week 
2. Yes, once a week 
3. Yes, only on weekends and special occasions 
4. I do not consume alcohol 
 
Part 5: Behavioral characteristics of the participants 
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Quiestionnare 2. Kazakh version 
1 Бөлім:  Қатысушылардың әлеуметтік  және демографиялық сипаттамалары 
 
 
Q1. Жасыңызды көрсетіңіз:________________________ 
Q2. Жынысыңызды белгілеңіз 
1. Әйел 
2. Ер адам 
 
Q3. Ұлтыңыз қандай? 
1. Қазақ 
2. Орыс 
3. Басқасы_____________________________ 
 
Q4. Қазір сіз нешінші курста оқып жатырсыз? 
1. 1-ші курс (бакалавр) 
2. 2-ші курс (бакалавр) 
3. 3-ші курс (бакалавр) 
4. 4-ші курс (бакалавр) 
5. 5-ші курс (бакалавр) 
6. Магистратура студенті (6-7 курс медицина студенті) 
 
 
Q5. Сіздің мамандығыңыз қандай? 
1. Гуманитарлық ғылымдар 
2. Әлеуметтік ғылымдар 
3. Өнер 
4. Заң 
5. Инжиниринг 
6. Жаратылыстану ғылымдары 
7. Математика және физика 
8. Медицина 
9. Қоғамдық денсаулық сақтау  
10. Фармацевтика бөлімі 
11. Басқасы 
 
Q6. Үлгеріміңізді қалай бағалайсыз? 
1. Өте жақсы 
2. Жақсы 
3. Қанағаттанарлық 
4. Қанағаттанарлықсыз 
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Q7. Сіз экономикалық жағдайыңызды қалай бағалайсыз? 
1. Жоғары табыс 
2. Орташа табыс 
3. Төмен табыс 
4. Басқасы (анықтап беріңіз): 
 
2 Бөлім: Денсаулыққа қатысты физикалық мәселелер туралы хабардарлық 
 
Q8. Қазіргі денсаулығыңыздың жағдайын жалпы қалай бағалар едіңіз? 
1. Өте жақсы 
2. Жақсы 
3. Қанағаттанарлық 
4. Нашар 
 
Q9. Денсаулыққа қатысты Сіздің жасыңызда болуы мүмкін, қандай мәселелерді қарастыра 
аласыз? 
 
 
 
Q10. Сіздің жасыңызда ауырып қалудың жалпы себептері қандай? 
 
 
 
Q11. Осы сауалнаманы өткізмес бұрын, сіз АПВ (адамның папиллома вирусы) туралы 
естідіңіз бе? 
1. Ия 
2. Жоқ 
 
Q12. Осы сауалнамаға дейін, сіз АПВ қарсы вакциналау туралы естідіңіз бе? 
1. Ия 
2. Жоқ (12ші сұраққа барыңыз) 
 
Q13. Алдыңғы сұраққа жауабыңыз «иә» болса, вакциналау туралы қай ақпарат 
дереккөзінен естідіңіз? 
1. БАҚ (жарнама, теледидар жаңалықтары, радио) 
2. Ғаламтор 
3. Дәрігер немесе гинеколог 
4. Университет дәрістері немесе профессорлар 
5. Отбасы 
6. Достар 
7. Басқалар, (анықтап беріңіз): 
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2 Бөлім: АПВ және АПВ вакциналау туралы хабардарлық бойынша сұрақтар 
 
      
Әр пікірдің тұсындағы бір жауапты шеңбермен  
         Белгілеңіз 
 
Дұрыс 
Дұрыс 
емес 
 
Білмеймін 
Q14. АПВ вагиналды, анал және ауыз жыныстық 
қатынаспен, сондай-ақ жыныстық органдар байланысу 
арқылы таратылуы мүмкін 
 
•   
 
•   •   
Q15. Адам папиллома вирусы жыныстық сүйелдер 
(жыныс мүшелерінің терісіндегі өсулер) қалыптасынуына 
әкелуі мүмкін 
•   •   •   
Q16. Адам папиллома вирусы герпесті тудыруы мүмкін 
 
•   •   •   
Q17. АПВ-ның әртүрлі түрлері бар 
 
•   •   •   
Q18. АПВ жатыр мойны обырын тудыруы мүмкін •   •   •   
Q19. Барлық АПВ-ның түрлері жатыр мойны обырына 
себеп болуы мүмкін 
 
•   •   •   
Q20. Тек қана әйелдер АПВ-н жұқтырып, ауру белгілерін 
көрсете алады 
•   •   •   
Q21. Көп жағдайларда, АПВ инфекциясы бар әйелдерде, 
ауру белгілері байқалмайды 
 
•   •   •   
Q22. Ауру таратқышында ауру белгісі болғанда ғана АПВ 
оның серіктесіне жұғуы  
•   •   •   
Q23. Әйел вакцинаны АПВ жұқтырғаннан бұрын немесе 
одан кейін қабылдаса да, вакцинаның әсері екі жағдайда 
да бірдей болады 
•   •   •   
Q24. АПВ вакцинасы жыныстық белсенділіктің 
басталуына дейін жақсы қабылданады 
 
•   •   •   
Q25. АПВ вакцинасы 18 жастан кейін ғана қабылданады •   •   •   
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26-37  сұрақтар үшін төмендегі пікірлермен келісетініңізді не келіспейтініңізді 
бағалауыңызды сұраймыз: 
 Толық
тай 
келісе
мін 
Келіс
емін 
Жауап 
беруге 
қиналамы
н 
Келіспе
ймін 
Толық
тай 
келіспе
ймін 
Q26. Өмір салтымды ескеретін болсам; АПВ-ның 
жұғуының жоғары қаупі бар дер ойлаймын 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q27. АПВ-ның алдын-алу үшін вакцина бар деп 
ойлаймын 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q28. Өмір салтымды ескеретін болсам; мен 
вакцина алудан пайда көретініме сенемін 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q29. Менің ойымша, қазақстандық студенттер 
АПВ инфекциясын жұқтыруға қаупы бар деп 
ойлаймын 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q30. Менің ойымша, қазақстандық студенттер 
АПВ вакцинасын алуға тиіс 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q31. Менің ойымша, АПВ вирусын жұқтырып 
алу өте қатерлі 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q32. Менің ойымша, АПВ  вирусын жұқтырып 
алу өмірге қауіпті болуы мүмкін 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q33. Менің ойымша, қазіргі  АПВ-ға қарсы 
вакцинасі жатыр мойны обырының пайда 
болуына кетергі жасайды 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q34. Вакцинаның қосалқы әсерлері ақылға 
қонымды деп есептеймін 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q35. Вакцинаның қосалқы әсерлері маған 
вакцина қабылдауға кедергі келтірмейді деп 
ойлаймын 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q36. Менің ойымша, барлық гинекологтар өз 
пациенттеріне вакцинаны ұсынуы керек 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q37. Мен бұл вакцинаны барлық әйел достарыма 
ұсынар едім 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
4 Бөлім: АПВ вакциналауына және АПВ инфекциясына қатысты көзқарастар 
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Q38. 1-10 шкаласы бойынша (1 ең ықтималсыз және 10 ең ықтималды) сіз қазір АПВ 
вакцинасынасын қабылдауға қаншалықты дайынсыз? (Бір нөмірді таңдаңыз) 
ең ықтималсыз ------------------------------------------------------------------------------ең ықтималды 
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
 
5 Бөлім: Қатысушылардың мінез-құлық сипаттамалары 
 
 
  
Q39. Сіздің өміріңізде жыныстық қатынастар бар ма? 
1. Ия 
2. Жоқ 
 
Q40. Сізде тұрақты жыныстық серіктесіңіз бар ма? 
1. Ия, мен үйленген адаммын 
2. Ия, мен адал қарым-қатынастамын 
3. Ия, бірақ мен тек бір жыныстық серіктеспен шектелмеймін 
4. Жоқ (41 сұраққа барыңыз) 
 
Q41. Сіз қандай контрацепцияны қолданасыз? 
1. Презерватив 
2. Дәрі 
3. Спираль 
4. Жақпа 
5. Мен пайдаланбаймын 
6. Басқасы (анықтаңыз) 
 
Q42. Сізде жыныстық жолмен берілетін инфекция (ЖЖБИ) (ВИЧ, герпес, гонорея, 
сифилис, В және С гепатиті) болды ма? 
1. Ия 
2. Жоқ 
 
Q43. Сіз ЖЖБИ тестілерінен өттіңіз ба? (оның ішінде АПВ тесті) 
1. Ия 
2. Жоқ 
 
Q44. Сіз дұрыс тамақтануды сақтаймын деп ойлайсыз ба? (ет, көкөніс және көмірсуларды 
өлшерлеп тамақтану) 
1. Ия 
2. Жоқ 
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Q45. Сіз темекі шегесіз бе? 
1. Иә, күнделікті 1-5 темекі 
2. Ия, күнделікті 6-10 темекі 
3. Ия, күніне 10-нан астам темекі  
4. Мен темекі шекпеймін 
 
Q46. Алкогольді сусындарды ішесіз бе? 
1. Ия, аптасына 3-7 рет 
2. Ия, аптасына бір рет 
3. Ия, демалыс күндері және ерекше жағдайларда ғана 
4. Мен алкогольді сусындарды ішпеймін 
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Questionnaire 3. Russian version                                                    
Раздел 1:  Социально -демографическиее характеристики участников 
 
 
Q1. Сколько вам лет? ____________ 
 
Q2. Укажите свой пол 
1. Мужской 
2. Женский 
 
Q3. Ваша национальность? 
1. Казах (казашка) 
2. Русский (русская) 
3. Другое_____________________________ 
 
 
Q4. На каком курсе вы сейчас учитесь? 
1. 1 курс бакалавриата 
2. 2-й курс бакалавриата 
3. 3-й курс бакалавриата  
4. 4-й курс бакалавриата 
5. 5- й курс бакалавриата 
6. Магистрант (в том числе, студенты-медики 6-7 курса ) 
7. Другое (пожалуйста,поясните):__________________________________________ 
 
Q5. Выберите свою специальность 
1. Гуманитарные науки 
2. Социальные науки 
3. Искусства 
4. Закон 
5. Инженерия 
6. Естественные науки 
7. Математика и физика 
8. Общая медицина 
9. Фармацевтическое дело 
10. Общественное здравоохранение 
11. Другое (пожалуйста, поясните):__________________________________________ 
Q6. Как вы оцениваете свою успеваемость? 
1. Отлично 
2. Хорошо 
3. Удовлетворительно 
4. Неудовлетворительно 
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Q7. В какую экономическую категорию, по вашему мнению вы себя относите? 
1. Высокий уровень дохода 
2. Средний уровень дохода 
3. Низкий уровень дохода 
4. Другое(пожалуйста, укажите ):___________________________________________ 
 
Раздел 2: Осведомленность о физических проблемах со здоровьем 
 
 
Q8. Как бы Вы в целом оценили свое нынешнее состояние здоровья? 
1. Отличное 
2. Хорошее  
3. Удовлетворительное  
4. Плохое 
 
Q9. Что вы считаете серьезными проблемами со здоровьем, которые характерны в  
вашем возрасте? 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
Q10. Что вы считаете общими причинами для получения заболевания в вашем возрасте? 
______________________________________________________________________________
______________________________________________________________________________ 
 
Q11. Перед проведением этого опроса вы когда-нибудь слышали о ВПЧ (Вирусе 
Паппиломы Человека)? 
1. да 
2. нет 
 
Q12. Перед тем, как принять этот опрос, вы когда-нибудь слышали о вакцине против 
ВПЧ? 
1. да 
2. нет (перейдите к Q14) 
 
Q13. Если «да», то с какого источника вы слышали о вакцине? 
1. сми (реклама, телевизионные новости, радио) 
2. интернет 
3. врач или гинеколог 
4. университетские лекции или профессора 
5. семья 
6. друзья 
7. другое (пожалуйста, укажите):___________________________________________ 
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Раздел 3: Вопросы об осведомленности о ВПЧ и вакцинации против ВПЧ  
 
 
      
Отметьте один из ответов в каждом утверждении 
 
Верно 
Не 
верно 
Не 
знаю 
(Q14- Q25) 
 
   
Q14. ВПЧ можно передавать через вагинальный, 
анальный и оральный секс, а также через контакт половых 
органов 
 
•   
 
•   •   
Q15. ВПЧ может привести к развитию генитальных 
бородавок (нарост на коже гениталий) 
 
•   •   •   
Q16. ВПЧ может привести к возникновению герпеса 
 
•   •   •   
Q17. Существуют различные виды ВПЧ 
 
•   •   •   
Q18. ВПЧ может вызвать рак шейки матки •   •   •   
Q19. Все типы ВПЧ могут вызывать рак шейки матки 
 
•   •   •   
Q20. Только женщины могут быть инфицированы ВПЧ и 
проявлять симптомы 
 
•   •   •   
Q21. В большинстве случаев инфицированные ВПЧ 
женщины не проявляют симптомов 
 
•   •   •   
Q22. ВПЧ может передаваться от переносчика к его / ее 
партнеру, только если переносчик обнаруживает 
симптомы 
 
•   •   •   
Q23.Вакцины против ВПЧ имеют тот же эффект, 
независимо от того, получают ли женщины вакцинацию 
до или после инфицирования ВПЧ 
•   •   •   
Q24. Вакцину против ВПЧ лучше всего принимать до 
начала половой жизни 
 
•   •   •   
Q25. Вакцина против ВПЧ может приниматься только 
после 18 лет 
 
•   •   •   
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Раздел 4: Вопросы об отношении к инфекции ВПЧ и вакцинации против ВПЧ 
 
 
Для вопросов Q26-Q37  оцените, пожалуйста,  свое 
согласие либо несогласие со следующими 
утверждениями: 
Полнос
тью 
соглас
ен 
Согла
сен 
Затрудня
юсь 
ответит
ь 
Не 
согласе
н 
Полнос
тью не 
согласе
н 
Q26. Основываясь на моем образе жизни, я 
считаю, что у меня повышенный риск заражения 
ВПЧ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Q2. Я считаю, что существует вакцина против 
ВПЧ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q28. Основываясь на моем образе жизни, я 
считаю, что я получу пользу от вакцинации 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q29. Я считаю, что казахстанские студенты 
имеют хорошие шансы заразиться ВПЧ 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q30. Я считаю, что казахстанские студенты 
должны получать вакцину против ВПЧ 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q31. Я считаю, что заражение вирусом ВПЧ 
является серьезным 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q32. Я считаю, что заражение ВПЧ может стать 
угрозой для жизни 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q33. Я считаю, что нынешняя вакцина против 
ВПЧ способна предотвратить появление рака 
шейки матки 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
Q34. Я считаю, что побочные эффекты вакцины 
приемлемы 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Q35. Я считаю, что побочные эффекты вакцины 
не удержат меня от принятия вакцины 
 
 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
Q36. Я считаю, что все гинекологи должны 
рекомендовать вакцину своим пациентам 
Q37. Я бы порекомендовал эту вакцину для моих      
подруг 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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Q38. По шкале от 1 до 10: 1 наименее вероятно, а 10 -  наиболее вероятно, насколько вы 
готовы сейчас принять вакцинацию против ВПЧ? (Выберите один номер) 
наименее вероятно--------------------------------------------------------------->наиболее вероятно 
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
 
 
Раздел 5: Поведенческие характеристики участников 
 
 
  
Q39. Вы живете половой жизнью? 
1. да 
2. нет 
 
Q40. У вас есть постоянный сексуальный партнер? 
1. да, я женат 
2. да, я состою в отношениях 
3. да, но я не ограничиваюсь только одним сексуальным партнером 
4. нет 
 
Q41. Какой вид контрацепции вы используете? 
1. презервативы 
2. противозачаточные таблетки 
3. спираль 
4. мазь 
5. я не использую 
6. другое(пожалуйста, укажите ):___________________________________________ 
 
Q42. Имели ли вы когда-либо инфекцию, передающуюся половым путем (ИППП) 
(например, ВИЧ, герпес, гонорея, сифилис, гепатит В и С)? 
1. да 
2. нет 
 
Q43. Проходили ли вы когда-либо тестирование на ИППП (включая тест на ВПЧ?) 
1. да 
2. нет 
 
Q44. Как вы думаете, вы поддерживаете здоровую диету? (например, вы едите 
сбалансированную пищу из мяса, овощей и углеводов) 
1. да 
2. нет 
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Q45. Вы курите? 
1. да, 1-5 сигарет ежедневно 
2. да, 6-10 сигарет ежедневно 
3. да, более 10 сигарет ежедневно 
4. я не курю 
 
Q46. Вы употребляете алкоголь? 
1. да, 3-7 раз в неделю 
2. да, раз в неделю 
3. да, только по выходным и специальным случаям 
4. я не употребляю алкоголь 
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Appendix 4. Consent form (English, Kazakh, Russian) 
Consent form 1. English version 
 Verbal Informed Consent 
Study Title: Knowledge and perception on human papillomavirus infection and vaccination 
among students of a university in Astana. 
Advisors: Azliyati Azizan, Raushan Alibekova 
I am Master of Public Health student in the Department of Public Health at the School of 
medicine at Nazarbayev University. This study will look at the topic of knowledge and 
awareness about HPV infection and attitudes towards HPV vaccination.   
Before we begin, let me describe what this study involves. After I’ve described the study to 
you, you can decide whether or not you would like to participate. 
I am conducting a survey to determine knowledge, awareness, and perception of human 
papillomavirus infection and vaccination. Moreover, the goal is to investigate the knowledge and 
awareness of HPV infection, attitudes towards HPV vaccination among university students and 
their intent to receive the HPV vaccine. I want to conduct this research among medical and non-
medical students of Astana. This study is important as it will allow knowing the current state of 
knowledge and attitudes regarding HPV among students.  
Participation should take about 15 minutes. Participation is voluntary. You will be asked to 
fill out the questionnaire with 46 questions. There are no risks expected that are greater than you 
would normally encounter in your daily life. Your participation will benefit my study. I will use 
this information obtained from you only for the purpose of the research. Your individual data 
will not be associated with your name in any way and will be kept confidential. 
You will not be penalized in any way for deciding to stop participation at any time.  If at 
any time you would like to stop participating, please tell me. We can take a break, stop and 
continue at a later date, or stop altogether. 
You will not receive any financial rewards for participating. However, you will make a 
great contribution for this research by participating in it.    
Do you have any questions? If you have questions later, you may contact the investigator, 
Master of Public Health student at the School of Medicine of Nazarbayev University. 
Are you interested in participating in this study? 
YES    [  ]   
NO   [  ] 
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Participants Identification Code (not name): 
  
Date: 
  
Time: 
  
Investigator: Torgyn Shokanbayeva 
  
Contact Information: 8-701-9512565, tshokanbaeva@nu.edu.kz 
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Verbal consent 2. Kazakh version 
Ауызша негізделген келісім 
 
Зерттеу тақырыбы: Астана  Студенттерінің Адам Папиллома Вирусы (АПВ) тұралы 
біліктілігі және АПВ вакциналауына көзқарасы 
Ғылыми жетекшілер: Әзлияти Әзизан, Раушан Әлібекова 
Мен Назарбаев Университетіндегі Медицина Мектебінің қоғамдық денсаулық сақтау 
кафедрасының магистра студентімін. Бұл зерттеу АПВ инфекциясы туралы және АПВ 
вакциналауына қатысты көзқарастар туралы білімді және хабардарлықты қарастырады. 
Бастамас бұрын, осы зерттеудің қысқаша сипаттамасын берейін. Сипаттама 
бергеннен кейін, сіз осы зерттеуге қатысу туралы шешім қабылдай аласыз. Зерттеудің 
мақсаты – Астанадағы студенттер арасында АПВ тұралы біліктілігті өлшеу және АПВ 
вакциналауына көзқарасын анықтау. Қазіргі таңда АПВ Қазақстан үшін медициналық 
және әлеуметтік жалпы мәселе болып саналады. Осы зерттеу студенттердің АПВ және 
АПВ вакциналауға қатысты сауаттылығын арттыру, сондай-ақ  студенттердің денсаулығы 
мен амандығын жақсарту үшін одан әрі даму салаларын анықтауға көмегін тигізеді деген 
үміттеміз. Осы тақырыпқа қатысты Сіздің пікіріңіз біз үшін өте маңызды. 
Сіз осы зерттеуге қатысу үшін кездейсоқ іріктеу әдісімен таңдалдыңыз. Осы 
сауалнаманы толтыруыңызды сұраймын. Толық құпиялылық және анонимдік 
сақталатынына кепілдік беремін, Сіздің жауаптарыңыз тек зерттеу мақсаттарында 
жалпыланған түрінде пайдаланылатын болады. Сауалнамада 46 сұрақ бар және оның 
ұзақтығы 15 минуттан аспайды. Сіздің аты-жөнінің анықталмайды және барлық ақпарат 
жасырын. Сізден атыңызды жазуыңыз немесе құжатқа қол қоюңызы сұралмайды.  
Бұл жоба сізге минималды тәуекел туғызады. Егер, қандай бір сұраққа жауап беру 
ыңғайсыздық туғызса, сұрақты аттып немесе сауалнамаға қатысудан бас тартуға болады. 
 
 
Сіз осы зерттеуге қатысуға қызығасыз ба? 
  
ИӘ [   ] 
ЖОҚ [   ] 
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Қатысушылардың сәйкестендіру коды (аты емес): 
  
Күні: 
  
Уақыты: 
  
Зерттеуші: Торғын Шоқанбаева 
  
Байланыс ақпараты: 8-701-9512565, tshokanbaeva@nu.edu.kz 
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Verbal consent 3. Russian version 
Устное информированное согласие 
 
Название исследования: Осведомленность и восприятие инфекции папилломавируса 
человека и вакцинации среди студентов г. Астана. 
Научные руководители : Азлияти Азизан, Раушан Алибекова 
Я студентка факультета общественного здравоохранения при Медицинской школе 
Назарбаев Университета. В этом исследовании будет рассмотрена тема знаний и 
осведомленности о ВПЧ-инфекции и отношение к вакцинации против ВПЧ. 
Прежде чем мы начнем, позвольте мне описать, что включает в себя это 
исследование. После того, как я расскажу вам об этом исследовании, вы можете решить, 
хотите ли вы принять участие. 
Я провожу опрос, чтобы определить знания, осведомленность и восприятие 
инфекции  и вакцинации против папилломавируса человека. Кроме того, целью этого 
опросника является исследование знаний и осведомленности о ВПЧ-инфекции, отношение 
к вакцинации против ВПЧ среди студентов университетов и их намерение получить 
вакцину против ВПЧ. Я хочу провести это исследование среди медицинских и 
немедицинских студентов Астаны. Это исследование имеет важное значение, поскольку 
оно позволяет узнать текущее состояние знаний и отношение к ВПЧ среди учащихся. 
Участие займет около 15 минут. Участие является добровольным. Вас попросят 
заполнить анкету с 46 вопросами. Нет никаких ожидаемых рисков, которые бы были 
выше, чем вы обычно встречали в своей повседневной жизни. Ваше участие принесет 
пользу моему исследованию. Я буду использовать информацию, полученную от вас,  
только для целей исследования. Ваши личные данные не будут связаны с вашим именем 
каким-либо образом и будут сохранены в конфиденциальности. 
Вы никоим образом не будете наказаны за принятие решения о прекращении участия 
в любое время. Если в любое время вы хотите прекратить участвовать, пожалуйста, 
скажите мне. Мы можем сделать перерыв, остановиться и продолжить позже, или вообще 
остановиться. 
Вы не получите никаких финансовых вознаграждений за участие. Тем не менее, вы 
внесете большой вклад в это исследование, участвуя в нем. 
У вас есть вопросы? Если у вас есть вопросы позже, вы можете обратиться к 
исследователю, магистранту факультета общественного здравоохранения в Медицинскую 
школу Назарбаев Университета. 
 
Вы заинтересованы в участии в этом исследовании?  
ДА    [  ] 
НЕТ  [  ] 
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Идентификационный код участников (не название): 
Дата: 
  
Время: 
  
Исследователь: Торгын Шоканбаева 
Контактная информация: 8-701-9512565, tshokanbaeva@nu.edu.kz 
 
 
